Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.65 |
| ▸ | TNKS | O95271 | 5/20 | 0.45 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.35 |
| ▸ | PARP3 | Q9Y6F1 | 3/20 | 0.35 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16366466 | 0.86 | PARP1 (0.71) | PARP1TNKSTTKAURKBINCENP | |
| SCHEMBL16366320 | 0.84 | PARP1 (0.68) | PARP1TNKSTTKAURKBINCENP | |
| SCHEMBL4815090 | 0.81 | PARP1 (0.89) | PARP1TNKSTTKAURKBINCENP | |
| SCHEMBL4154686 | 0.79 | PARP1 (1.00) | PARP1TNKSTTKAURKBINCENP | |
| SCHEMBL30859698 | 0.79 | PARP1 (1.00) | PARP1TNKSTTKAURKBINCENP | |
| Hydrochloric Acid SCHEMBL4816152 | 0.78 | PARP1 (0.98) | PARP1TNKSTTKAURKBINCENP | |
| Bromide SCHEMBL4816768 | 0.78 | PARP1 (0.98) | PARP1TNKSTTKAURKBINCENP | |
| SCHEMBL4816105 | 0.70 | PARP1 (0.80) | PARP1ROCK2NAMPTROCK1 | |
| SCHEMBL14064731 | 0.70 | PARP1 (0.80) | PARP1TNKSROCK2NAMPTROCK1 | |
| SCHEMBL4815278 | 0.68 | PARP1 (0.78) | PARP1ROCK2NAMPTNEK1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425563-B2 | Excellent poly (ADP-ribose) synthetase inhibitors; various ischemic diseases, inflammatory diseases, neurodegenerative diseases, diabetes, septic shock, cephalic injury; 1,2-Dihydro-4-[4-(dimethylaminomethyl)phenyl]-5-hydroxy-1-oxoisoquinoline | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-20060173039-A1 | 4-(Substituted aryl)-5-hydroxyisoquinolinone derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-03 | — | — | US | disclosed |
| EP-1544194-A1 | 4-(SUBSTITUTED ARYL)-5-HYDROXYISOQUINOLINONE DERIVATIVE | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173039-A1 | 4-(Substituted aryl)-5-hydroxyisoquinolinone derivative | PARP1, PARP11, PARP4 | PARP1 1/4885TNKS 45/4885TTK 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.